| Primary |
| Product Used For Unknown Indication |
18.7% |
| Acute Coronary Syndrome |
16.9% |
| Hypertension |
8.3% |
| Coronary Artery Disease |
8.2% |
| Antiplatelet Therapy |
7.9% |
| Drug Use For Unknown Indication |
6.9% |
| Acute Myocardial Infarction |
6.1% |
| Atrial Fibrillation |
3.7% |
| Stent Placement |
2.8% |
| Cerebrovascular Accident |
2.5% |
| Coronary Arterial Stent Insertion |
2.5% |
| Myocardial Infarction |
2.2% |
| Prophylaxis |
2.1% |
| Diabetes Mellitus |
1.9% |
| Thrombosis Prophylaxis |
1.9% |
| Angina Unstable |
1.8% |
| Anticoagulant Therapy |
1.5% |
| Hyperlipidaemia |
1.4% |
| Lacunar Infarction |
1.4% |
| Cerebral Ischaemia |
1.4% |
|
| Thrombosis In Device |
12.9% |
| Vascular Pseudoaneurysm |
12.0% |
| Rectal Haemorrhage |
7.4% |
| Gastric Haemorrhage |
6.5% |
| Death |
5.5% |
| Cardiac Tamponade |
5.3% |
| Gastrointestinal Haemorrhage |
4.6% |
| Haemorrhage |
4.6% |
| Vomiting |
4.6% |
| Product Substitution Issue |
4.4% |
| Melaena |
3.7% |
| Subdural Haematoma |
3.7% |
| Thrombocytopenia |
3.5% |
| Upper Gastrointestinal Haemorrhage |
3.5% |
| Thrombosis |
3.2% |
| Haemoglobin Decreased |
3.0% |
| Rash |
3.0% |
| Renal Impairment |
3.0% |
| Syncope |
2.8% |
| Transient Ischaemic Attack |
2.8% |
|
| Secondary |
| Drug Use For Unknown Indication |
19.1% |
| Product Used For Unknown Indication |
15.8% |
| Acute Coronary Syndrome |
11.0% |
| Acute Myocardial Infarction |
7.2% |
| Antiplatelet Therapy |
5.8% |
| Percutaneous Coronary Intervention |
5.1% |
| Myocardial Infarction |
4.3% |
| Cerebrovascular Accident Prophylaxis |
4.3% |
| Hypertension |
3.8% |
| Coronary Artery Disease |
3.7% |
| Anticoagulant Therapy |
3.4% |
| Atrial Fibrillation |
2.9% |
| Thrombosis Prophylaxis |
2.6% |
| Stent Placement |
1.9% |
| Coronary Arterial Stent Insertion |
1.8% |
| Prophylaxis |
1.8% |
| Diabetes Mellitus |
1.7% |
| Angina Pectoris |
1.4% |
| Hypercholesterolaemia |
1.3% |
| Hiv Infection |
1.1% |
|
| Thrombosis In Device |
14.9% |
| Completed Suicide |
10.1% |
| Vascular Pseudoaneurysm |
9.5% |
| Thrombocytopenia |
8.1% |
| Gastrointestinal Haemorrhage |
5.1% |
| Vomiting |
5.1% |
| Haemoglobin Decreased |
4.5% |
| Renal Failure Acute |
4.2% |
| Haemorrhage |
3.9% |
| Myocardial Infarction |
3.8% |
| Rectal Haemorrhage |
3.8% |
| Renal Failure |
3.8% |
| Upper Gastrointestinal Haemorrhage |
3.7% |
| Death |
3.3% |
| Haemorrhage Intracranial |
3.1% |
| Melaena |
3.0% |
| Drug Interaction |
2.7% |
| International Normalised Ratio Increased |
2.5% |
| Nausea |
2.5% |
| Sepsis |
2.5% |
|
| Concomitant |
| Product Used For Unknown Indication |
28.1% |
| Drug Use For Unknown Indication |
26.1% |
| Hypertension |
9.7% |
| Acute Myocardial Infarction |
3.9% |
| Myocardial Infarction |
2.8% |
| Rheumatoid Arthritis |
2.8% |
| Diabetes Mellitus |
2.6% |
| Prophylaxis |
2.6% |
| Coronary Artery Disease |
2.4% |
| Cardiac Disorder |
2.3% |
| Blood Cholesterol Increased |
2.0% |
| Pain |
2.0% |
| Acute Coronary Syndrome |
1.9% |
| Percutaneous Coronary Intervention |
1.7% |
| Anticoagulant Therapy |
1.7% |
| Type 2 Diabetes Mellitus |
1.6% |
| Atrial Fibrillation |
1.6% |
| Depression |
1.5% |
| Hypercholesterolaemia |
1.4% |
| Angina Pectoris |
1.4% |
|
| Myocardial Infarction |
10.6% |
| Rhabdomyolysis |
8.5% |
| Vomiting |
8.3% |
| Renal Failure Acute |
6.6% |
| Weight Decreased |
6.2% |
| Thrombocytopenia |
5.3% |
| Death |
5.1% |
| Flushing |
5.0% |
| Cerebrovascular Accident |
4.8% |
| Thrombosis In Device |
4.8% |
| Nausea |
4.2% |
| Pneumonia |
4.2% |
| Pruritus |
3.7% |
| Syncope |
3.6% |
| Ventricular Tachycardia |
3.5% |
| Transient Ischaemic Attack |
3.2% |
| Urinary Tract Infection |
3.2% |
| Pain In Extremity |
3.1% |
| Drug Ineffective |
3.0% |
| Paraesthesia |
3.0% |
|
| Interacting |
| Product Used For Unknown Indication |
14.7% |
| Acute Coronary Syndrome |
14.3% |
| Drug Use For Unknown Indication |
9.4% |
| Angina Pectoris |
7.9% |
| Angioplasty |
7.5% |
| Periorbital Cellulitis |
6.4% |
| Mycobacterium Avium Complex Infection |
5.8% |
| Acute Myocardial Infarction |
4.6% |
| Stent Placement |
4.2% |
| Atrial Fibrillation |
2.9% |
| Chest Pain |
2.9% |
| Antiplatelet Therapy |
2.7% |
| Thrombosis Prophylaxis |
2.6% |
| Cerebrovascular Accident Prophylaxis |
2.2% |
| Coronary Artery Disease |
2.2% |
| Ill-defined Disorder |
2.1% |
| Myocardial Infarction |
2.1% |
| Hypertension |
2.0% |
| Prophylaxis |
1.8% |
| Pulmonary Embolism |
1.8% |
|
| Drug Interaction |
15.1% |
| Thrombosis In Device |
14.1% |
| Subdural Haemorrhage |
9.2% |
| Pyrexia |
8.6% |
| Gastrointestinal Haemorrhage |
5.9% |
| Vascular Pseudoaneurysm |
4.9% |
| Post Procedural Haemorrhage |
4.3% |
| Puncture Site Haemorrhage |
4.3% |
| Cerebral Haemorrhage |
3.8% |
| Syncope |
3.8% |
| International Normalised Ratio Increased |
3.2% |
| Sudden Death |
3.2% |
| Haemoglobin Decreased |
2.7% |
| Lower Gastrointestinal Haemorrhage |
2.7% |
| Rhabdomyolysis |
2.7% |
| Upper Gastrointestinal Haemorrhage |
2.7% |
| Anaemia |
2.2% |
| Haemorrhage |
2.2% |
| Myocardial Infarction |
2.2% |
| Renal Failure Acute |
2.2% |
|
